STOCK TITAN

[Form 4] AYTU BIOPHARMA, INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Officer grant and ownership change: The Chief Commercial Officer received a grant of 12,500 restricted shares of common stock that vest over time, increasing his beneficial ownership to 36,102 shares. The award was issued at a price of $0, indicating a stock-based compensation grant rather than a cash purchase. One-third of the restricted shares vest on 10/03/2026, with the remaining shares vesting in eight equal quarterly installments beginning 01/03/2027.

This transaction is a non-derivative, officer-level compensation event that aligns the officer's interests with shareholders through time-based vesting. The restricted nature of the shares means transfer or sale will be limited until vesting occurs.

Assegnazione al dirigente e cambiamento di proprietà: Il Chief Commercial Officer ha ricevuto una concessione di 12.500 azioni ordinarie restritte che maturano nel tempo, aumentando la sua proprietà beneficiaria a 36.102 azioni. L'assegnazione è stata emessa al prezzo di $0, indicando una concessione di compensazione basata su azioni piuttosto che un acquisto in contanti. Un terzo delle azioni restritte matura il 10/03/2026, con le restanti azioni che maturano in otto rate trimestrali uguali a partire dal 01/03/2027.

Questa operazione è un evento di compensazione non derivato a livello di dirigente che allinea gli interessi del dirigente con quelli degli azionisti tramite una maturazione basata sul tempo. La natura restritta delle azioni implica che il trasferimento o la vendita saranno limitati fino a maturazione avvenuta.

Concesión de nombramiento de oficial y cambio de propiedad: El Director Comercial obtuvo una concesión de 12.500 acciones restringidas comunes que se consolidan con el tiempo, aumentando su titularidad beneficiosa a 36.102 acciones. La adjudicación se emitió a un precio de $0, lo que indica una adjudicación de compensación basada en acciones en lugar de una compra en efectivo. Un tercio de las acciones restringidas se consolidan el 10/03/2026, y las acciones restantes se consolidarán en ocho cuotas trimestrales iguales a partir del 01/03/2027.

Esta transacción es un evento de compensación a nivel de oficial sin derivados que alinea los intereses del oficial con los de los accionistas mediante la consolidación temporal. La naturaleza restringida de las acciones implica que la transferencia o venta estará limitada hasta que se consoliden.

임원 수여 및 소유권 변경: 최고 상무 이사는 시간에 따라 vesting되는 12,500 제한 주식을 수여받았으며, 이를 통해 그의 이익 소유권이 36,102 주로 증가했습니다. 수상은 $0의 가격으로 발행되어 현금 구매가 아닌 주식 기반 보상 수여를 나타냅니다. 제한 주식의 3분의 1은 2026-10-03에 vesting되며, 나머지 주식은 2027-01-03부터 시작하는 8개의 동일한 분기별 분할로 vesting됩니다.

이 거래는 파생상품이 없는 임원 수준의 보상 사건으로, 시간 기반 vesting을 통해 임원의 이해관계를 주주와 일치시킵니다. 주식의 제한된 특성상 vesting이 이루어질 때까지 양도나 매각은 제한됩니다.

Attribution à un officier et changement de propriété : Le directeur commercial a reçu une attribution de 12 500 actions ordinaires restreintes qui se consolident avec le temps, augmentant sa propriété bénéficiaire à 36 102 actions. L'attribution a été émise à un prix de $0, indiquant une attribution de compensation basée sur les actions plutôt qu'un achat en espèces. Un tiers des actions restreintes se consolident le 10/03/2026, le reste des actions se consolidant en huit versements trimestriels égaux à partir du 01/03/2027.

Cette transaction est un événement de rémunération non dérivé au niveau de l'officier qui aligne les intérêts de l'officier sur ceux des actionnaires grâce à une consolidation dans le temps. La nature restreinte des actions signifie que le transfert ou la vente sera limité jusqu'à la consolidation.

Aufstellung des Officers und Eigentumsänderung: Der Chief Commercial Officer erhielt eine Zuteilung von 12.500 eingeschränkten Stammaktien, die sich im Laufe der Zeit vesten, wodurch sich sein beneficial ownership auf 36.102 Aktien erhöht. Die Zuteilung wurde zu einem Preis von $0 ausgegeben, was darauf hinweist, dass es sich um eine aktienbasierte Vergütung handelt statt eines Barkaufs. Ein Drittel der eingeschränkten Aktien vestet am 10/03/2026, die verbleibenden Aktien vesten in acht gleichen vierteljährlichen Raten, beginnend am 01/03/2027.

Diese Transaktion ist ein nicht-derivativer, auf Offizier Ebene stattfindender Vergütungsfall, der die Interessen des Offiziers durch zeitbasierte Vesting mit denen der Aktionäre in Einklang bringt. Die eingeschränkte Natur der Aktien bedeutet, dass Übertragung oder Verkauf bis zum Vesting eingeschränkt ist.

منحة مسؤول وتغيير الملكية: تلقّى المدير التنفيذي التجاري عرضاً لــ 12,500 أسهم عادية مقيدة تتيسر بموجبها تدريجيًا، مما يزيد من ملكيته المفيدة إلى 36,102 سهماً. تم إصدار الجائزة بسعر $0، مما يشير إلى منحة تعويض قائمة على الأسهم بدلاً من شراء نقدي. سيتحقق ملكية جزء من الأسهم المقيدة بمقدار الثلث في 10/03/2026، أما الأسهم المتبقية فستتحقق على مدى ثمانية دفعات ربع سنوية متساوية ابتداءً من 01/03/2027.

هذه المعاملة هي حدث تعويض غير مشتق على مستوى المسؤول يهدف إلى مواءمة مصلحة المسؤول مع مصالح المساهمين من خلال التحقُق على مدى الزمن. بطبيعة الأمر المقيد، سيكون النقل أو البيع مقيداً حتى يحدث الاستحقاق.

高管授予与所有权变更: 首席商务官获得了< b>12,500份受限普通股,这些股票将随时间逐步归属,其实际持股增至36,102股。此授予以$0的价格发行,表明这是基于股票的补偿,而非现金购买。受限股中的三分之一将于2026-10-03归属,其余股份将从2027-01-03起分8个等额的季度分期归属。

此次交易属于非衍生、面向高管的补偿事件,通过时间基的归属将高管利益与股东利益对齐。由于股票具有受限属性,在归属前转让或出售受限。

Positive
  • 12,500 restricted shares granted to the Chief Commercial Officer, increasing alignment with shareholders
  • Vesting schedule includes a meaningful cliff: 1/3 vests on 10/03/2026, then structured quarterly vesting
Negative
  • Grant issued at $0 (compensation expense) which will be recorded when recognized
  • Additional shares become available on vesting, increasing potential dilution to existing holders

Insights

Time‑based restricted stock aligns CCO incentives with long-term share performance.

The grant of 12,500 restricted shares to the Chief Commercial Officer increases his direct holdings to 36,102 and is structured with a clear vesting schedule: one‑third on 10/03/2026 and the remainder in eight equal quarterly installments starting 01/03/2027.

This design ties realized value to tenure and market performance while delaying full dilution until vesting dates. Monitor forthcoming periodic filings for recognition of compensation expense and any updates if vesting conditions change within the next 12–18 months.

Assegnazione al dirigente e cambiamento di proprietà: Il Chief Commercial Officer ha ricevuto una concessione di 12.500 azioni ordinarie restritte che maturano nel tempo, aumentando la sua proprietà beneficiaria a 36.102 azioni. L'assegnazione è stata emessa al prezzo di $0, indicando una concessione di compensazione basata su azioni piuttosto che un acquisto in contanti. Un terzo delle azioni restritte matura il 10/03/2026, con le restanti azioni che maturano in otto rate trimestrali uguali a partire dal 01/03/2027.

Questa operazione è un evento di compensazione non derivato a livello di dirigente che allinea gli interessi del dirigente con quelli degli azionisti tramite una maturazione basata sul tempo. La natura restritta delle azioni implica che il trasferimento o la vendita saranno limitati fino a maturazione avvenuta.

Concesión de nombramiento de oficial y cambio de propiedad: El Director Comercial obtuvo una concesión de 12.500 acciones restringidas comunes que se consolidan con el tiempo, aumentando su titularidad beneficiosa a 36.102 acciones. La adjudicación se emitió a un precio de $0, lo que indica una adjudicación de compensación basada en acciones en lugar de una compra en efectivo. Un tercio de las acciones restringidas se consolidan el 10/03/2026, y las acciones restantes se consolidarán en ocho cuotas trimestrales iguales a partir del 01/03/2027.

Esta transacción es un evento de compensación a nivel de oficial sin derivados que alinea los intereses del oficial con los de los accionistas mediante la consolidación temporal. La naturaleza restringida de las acciones implica que la transferencia o venta estará limitada hasta que se consoliden.

임원 수여 및 소유권 변경: 최고 상무 이사는 시간에 따라 vesting되는 12,500 제한 주식을 수여받았으며, 이를 통해 그의 이익 소유권이 36,102 주로 증가했습니다. 수상은 $0의 가격으로 발행되어 현금 구매가 아닌 주식 기반 보상 수여를 나타냅니다. 제한 주식의 3분의 1은 2026-10-03에 vesting되며, 나머지 주식은 2027-01-03부터 시작하는 8개의 동일한 분기별 분할로 vesting됩니다.

이 거래는 파생상품이 없는 임원 수준의 보상 사건으로, 시간 기반 vesting을 통해 임원의 이해관계를 주주와 일치시킵니다. 주식의 제한된 특성상 vesting이 이루어질 때까지 양도나 매각은 제한됩니다.

Attribution à un officier et changement de propriété : Le directeur commercial a reçu une attribution de 12 500 actions ordinaires restreintes qui se consolident avec le temps, augmentant sa propriété bénéficiaire à 36 102 actions. L'attribution a été émise à un prix de $0, indiquant une attribution de compensation basée sur les actions plutôt qu'un achat en espèces. Un tiers des actions restreintes se consolident le 10/03/2026, le reste des actions se consolidant en huit versements trimestriels égaux à partir du 01/03/2027.

Cette transaction est un événement de rémunération non dérivé au niveau de l'officier qui aligne les intérêts de l'officier sur ceux des actionnaires grâce à une consolidation dans le temps. La nature restreinte des actions signifie que le transfert ou la vente sera limité jusqu'à la consolidation.

Aufstellung des Officers und Eigentumsänderung: Der Chief Commercial Officer erhielt eine Zuteilung von 12.500 eingeschränkten Stammaktien, die sich im Laufe der Zeit vesten, wodurch sich sein beneficial ownership auf 36.102 Aktien erhöht. Die Zuteilung wurde zu einem Preis von $0 ausgegeben, was darauf hinweist, dass es sich um eine aktienbasierte Vergütung handelt statt eines Barkaufs. Ein Drittel der eingeschränkten Aktien vestet am 10/03/2026, die verbleibenden Aktien vesten in acht gleichen vierteljährlichen Raten, beginnend am 01/03/2027.

Diese Transaktion ist ein nicht-derivativer, auf Offizier Ebene stattfindender Vergütungsfall, der die Interessen des Offiziers durch zeitbasierte Vesting mit denen der Aktionäre in Einklang bringt. Die eingeschränkte Natur der Aktien bedeutet, dass Übertragung oder Verkauf bis zum Vesting eingeschränkt ist.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PYSZCZYMUKA GREG

(Last) (First) (Middle)
C/O AYTU BIOPHARMA, INC.
7900 EAST UNION AVENUE, SUITE 920

(Street)
DENVER CO 80237

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Commercial Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/03/2025 A 12,500(1) A $0 36,102 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Grant of restricted stock, which vest as follows: 1/3 on October 3, 2026, with the remaining restricted stock vesting in 8 equal quarterly installments beginning January 3, 2027.
Remarks:
Exhibit 24: Power of Attorney
/s/ Ryan J. Selhorn as attorney-in-fact for Greg Pyszczymuka 10/07/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AYTU insider Greg Pyszczymuka receive?

He received a grant of 12,500 restricted common shares that vest over time, bringing his holdings to 36,102 shares.

At what price were the restricted shares granted to the AYTU CCO?

The restricted shares were granted at a price of $0, indicating a compensatory grant rather than a purchase.

When do the restricted shares vest for the AYTU grant?

One‑third vests on 10/03/2026, with the remaining shares vesting in eight equal quarterly installments beginning 01/03/2027.

How many AYTU shares does the reporting person own after the grant?

The reporting person beneficially owns 36,102 shares following the reported transaction.

Is this transaction a purchase or a compensatory award?

This is a compensatory restricted stock grant (non‑derivative) issued at $0.
Aytu Biopharma Inc

NASDAQ:AYTU

AYTU Rankings

AYTU Latest News

AYTU Latest SEC Filings

AYTU Stock Data

24.88M
9.15M
7.58%
38.09%
5.17%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
DENVER